CA14 as A Cancer Drug Target: Promising Biomarker (G23632)

Target Name: CA14

NCBI ID: G23632

CA14

CA14 as A Cancer Drug Target: Promising Biomarker

Cancer has one of the highest mortality rates worldwide, and the development and progression of cancer are a continuous challenge for healthcare providers. The identification of potential drug targets and biomarkers is a critical step in the fight against cancer. One such potential drug target is CA14 (CA-XIV), which has been identified as a promising biomarker for the diagnosis and prognosis of various types of cancer.

CA14 is a carbohydrate derived from the cell surface of cancer cells. It is expressed in high levels in cancer tissues and has been identified as a potential drug target in various types of cancer, including breast, ovarian, and prostate cancers. The exact mechanism of how CA14 promotes cancer growth and progression is not yet fully understood, but research has shown that it plays a significant role in the development and progression of cancer.

One of the key functions of CA14 is its role in cell signaling. CA14 is a potent negative regulator of the TGF-β signaling pathway, which is a well-known driver of cancer growth and progression. The TGF-β pathway is responsible for promoting cell growth, angiogenesis, and the formation of invasive and metastatic tissues. By inhibiting the TGF-β pathway, CA14 has been shown to have a negative impact on cancer cell growth and development.

In addition to its role in cell signaling, CA14 has also been shown to play a key role in the regulation of cell adhesion. Cancer cells have unique requirements for cell adhesion in order to maintain their structural integrity and to form a invasive and metastatic organization. CA14 has been shown to regulate cell adhesion by modulating the interactions between adhesion molecules and the cytoskeleton.

Another function of CA14 is its role in cancer angiogenesis. Cancer cells require a healthy supply of blood vessels to maintain their growth and progression. CA14 has been shown to regulate the formation and function of blood vessels in cancer tissues, which is a critical step in the development of new blood vessels that feed the tumor.

In conclusion, CA14 is a promising biomarker for the diagnosis and prognosis of various types of cancer. Its role in cell signaling, regulation of cell adhesion, and cancer angiogenesis makes it an attractive target for drug development. Further research is needed to fully understand the mechanism of CA14 and its potential as a drug target.

Protein Name: Carbonic Anhydrase 14

Functions: Reversible hydration of carbon dioxide

The "CA14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CA14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets